4h
Barchart on MSNHow Is Gilead Sciences' Stock Performance Compared to Other Pharmaceutical Stocks?Valued at a market cap of $143.8 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company that discovers, ...
Louise Lipman wasn’t looking for a townhouse or at the east side of Toronto. But she says 11B Gilead Place got ‘imprinted’ on ...
The pharmaceutical powerhouse has two drugs that disrupt the transmission of the virus, one of which has been approved for ...
One of Hulu’s first original series is coming the beginning of the end on Hulu. When does ’The Handmaid’s Tale’ return?
As The Handmaid’s Tale is about to air its final season, Hulu is preparing to dive into another series based on a novel by ...
Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...
1d
Zacks Investment Research on MSNGilead Sciences, Inc. (GILD) Hits Fresh High: Is There Still Room to Run?Shares have been on the move with the stock up 17.1% over the past month. The stock hit a new 52-week high of $117.39 in the previous session. Gilead Sciences has gained 24.2% since the start of the ...
BofA raised the firm’s price target on Gilead (GILD) to $126 from $116 and keeps a Buy rating on the shares. For the last several weeks, ...
At the Mount Gilead Exempted Village Schools Board of Education meeting on Feb. 18, Superintendent Zack Howard announced ...
With over seven years of experience in data science and analytics, Nidhi has led high-impact projects at leading healthcare ...
Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report ...
Shares of Gilead Sciences Inc. GILD shed 1.08% to $114.74 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 1.22% to 5,778.15 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results